A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Condition:   Lymphoma, Large B-Cell, Diffuse Interventions:   Biological: Zilovertamab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Biological: Rituximab;   Biological: Rituximab Biosimilar;   Drug: Prednisone;   Drug: Prednisolone Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials